Navigation Links
Goodwin Biotechnology Announces the Appointment of SooYoung S. Lee, PhD as Chief Operating Officer
Date:9/12/2013

PLANTATION, Fla., Sept. 12, 2013 /PRNewswire/ -- Goodwin Biotechnology, Inc.  announced a key appointment that is designed to position the company for the future. SooYoung Lee, PhD has returned to Goodwin Biotechnology as Chief Operating Officer. He will report to newly appointed CEO, Karl Pinto, and will oversee all aspects of Goodwin's Contract Manufacturing Operations.

SooYoung has had a distinguished career in the biological industry spanning several decades.  After earning his PhD in Biochemical Engineering at Cornell University, he held several  leadership positions at leading biopharmaceutical companies and CMO's such as SAIC – Frederick, Schering-Plough Research Institute, Wyeth – Lederle Vaccines, AppTec, Neose Technologies and Genencor. He also has extensive experience in international biotechnology operations, having established and served as the Director of the Biopharmaceutical Manufacturing Technology Center (BMTC) in Singapore, and as a Senior Member, he helped establish the International Vaccine Institute (IVI) in Seoul, Korea. 

"I am excited about the opportunity to team up with the dedicated staff at Goodwin Biotechnology," said SooYoung Lee, PhD.  "Since its inception in 1992, the company has a distinguished history and a great track record of providing quality Contract Development and Manufacturing services and GMP clinical material as the first comprehensive CMO focusing on cell culture-based biologics. Our goal is to continue working with our clients as a development and manufacturing partner to manufacture cGMP compliant clinical trial material in a timely and cost-effective manner. Being uniquely flexible in our client engagements and shortening the time from bench to clinic will have a critical impact on the success of our partners and ultimately benefit patients and their families." 

"SooYoung's experiences in process development, tech transfer and GMP manufacturing along with strategic planning and execution will help ensure the delivery of the highest quality services and products that are in compliance with current Good Manufacturing Practices (cGMP) to our clients, ranging from the smallest biotech start-ups to large biopharma companies," noted Karl Pinto. "With this significant addition, we are poised to take the company to new heights."

About Goodwin Biotechnology, Inc.

Goodwin Biotechnology is a world-class CMO that offers a Single Source Solution™ through partnerships with clients for cell line development or exploratory proof of concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines and Antibody Drug Conjugates (ADCs) for early and late stage clinical trials. By working with GBI, our clients can enhance the value of their product candidates with clear development and manufacturing strategies as well as a road map to meet the highest quality product requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical approval pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients' lives. With over 20 years of experience as an independent contract manufacturer, GBI has worked as a strategic partner with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Additional information may be found at www.GoodwinBio.com.

For more information on the process development and GMP manufacturing of biologics, please contact Goodwin Biotechnology:

Robin McCallum 
Business Development Manager 
(954) 327-9656  
RMcCallum@GoodwinBio.com


'/>"/>
SOURCE Goodwin Biotechnology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Goodwin Biotechnology Announces Process Development Sub-Contract for an Anthrax Vaccine
2. Goodwin Biotechnology is a Three-Category Winner in the 2012 CMO Leadership Awards
3. Jeannette R. Jakus, MD, MBA, Awarded American Academy of Dermatology Translational Biotechnology Fellowship
4. TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States
5. Cytos Biotechnology Ltd Reports Second Quarter 2013 Financial Results and Recent Developments
6. The Galien Foundation Announces 2013 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
7. ResearchMoz.us: Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing & Others) - Global Industry Analysis, Size, Share, Growt
8. Platine Pharma Services et Indicia Biotechnology se rapprochent pour renforcer leur leadership en immunomonitoring
9. Sony Biotechnology Inc.s New Technology for Science Provides Researchers Results in Color
10. Plandai Biotechnology, Inc. Announces Formation Of New Entity To Develop Pharmaceutical Applications
11. Increased Dosage of Needle-Free Erectile Dysfunction Medication TriMix-gel Now Available through KRS Global Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Dec. 5, 2016   BIOTRONIK today announced ... The study evaluates the safety and feasibility of performing ... office setting. BioMonitor 2 is an insertable ... is placed underneath a patient,s skin to help physicians ... Atrial fibrillation is a leading cause of stroke and ...
(Date:12/5/2016)... , Dec. 5, 2016  Wellbridge Health and Gateway Health ... health solutions to Medicare and Medicaid plan members with specific ... at the unique needs of this group of consumers, Wellbridge ... work philosophies to provide insight into members, daily behaviors and ... , , ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 /PRNewswire/ ... announced preliminary safety and efficacy data from a ... selective MDM2 inhibitor, suggesting that DS-3032 may be ... acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome ... of the phase 1 study of DS-3032 were presented ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is a tool ... effect without heavy rendering or complicated compositing," said Christina Austin - CEO of Pixel ... an organic spectrum of lights that simulates the look of a glare. Just ...
(Date:12/5/2016)... ... December 06, 2016 , ... For many years, Andrew G. ... thick and thin. The beauty of the Lithuanian language and its poetry ... this poetry book, Zubinas lyrically explores all aspects of a living, breathing forest where ...
(Date:12/5/2016)... ... 2016 , ... Researchers at Johns Hopkins All Children’s Hospital want to learn ... the course of three years, researchers will study concussions and changes in brain function ... with special sensors, will track the location and force of the hit. The sensors ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... a patent-pending blend of L-Citrulline and glutathione to enhance production of nitric oxide ... that studies have shown to produce NO twice as effectively and sustains NO ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... and geographic lines. The goal of Castlewood Treatment Centers has always been to ... accessible to as many people as possible. In that spirit, Castlewood has announced ...
Breaking Medicine News(10 mins):